¼¼°èÀÇ ÁÂ½É½Ç º¸Á¶ ÀåÄ¡(LVAD) ½ÃÀå
Left Ventricular Assist Device (LVAD)
»óǰÄÚµå : 1559734
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 182 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÁÂ½É½Ç º¸Á¶ ÀåÄ¡(LVAD) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 26¾ï ´Þ·¯¿¡ µµ´Þ

2023³â¿¡ 15¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÁÂ½É½Ç º¸Á¶ ÀåÄ¡(LVAD) ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ 2023-2030³â¿¡ CAGR 7.6%·Î ¼ºÀåÇϰí 2030³â¿¡´Â 26¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ º´¿ø ÃÖÁ¾ ¿ëµµ´Â CAGR 6.1%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á±îÁö 13¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ŭ¸®´Ð ÃÖÁ¾ ¿ëµµ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 9.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 2,340¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÁÂ½É½Ç º¸Á¶ ÀåÄ¡(LVAD) ½ÃÀåÀº 2023³â 4¾ï 2,340¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2023-2030³â CAGR 7.2%¸¦ ÂÑ¾Æ 2030³â±îÁö 4¾ï270¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 6.8%¿Í 6.4%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 6.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÁÂ½É½Ç º¸Á¶ ÀåÄ¡(LVAD) ½ÃÀå- ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÁÂ½É½Ç º¸Á¶ ÀåÄ¡(LVAD)¶õ ¹«¾ùÀΰ¡?

ÁÂ½É½Ç º¸Á¶ ÀåÄ¡(LVAD)´Â ½ÉÀåÀÌ ¾àÇÑ »ç¶÷°ú ½É°¢ÇÑ ½ÉºÎÀüÀ» °¡Áø »ç¶÷ÀÇ ½ÉÀå ±â´É°ú Ç÷·ù¸¦ Áö¿øÇÏ´Â µ¥ »ç¿ëµÇ´Â ±â°èÀû ÆßÇÁÀÔ´Ï´Ù. LVAD´Â ÀϹÝÀûÀ¸·Î Ä¡·á°¡ ´õ ÀÌ»ó À¯È¿ÇÏÁö ¾ÊÀ» ¶§ »ç¿ëµÇ¸ç ½ÉÀå À̽Ŀ¡ ´ëÇÑ ±³·®À¸·Î ȯÀÚ°¡ ±âÁõÀÚÀÇ ½ÉÀåÀ» ±â´Ù¸®´Â µ¿¾È Áß¿äÇÑ Áö¿øÀ» Á¦°øÇÕ´Ï´Ù. ´ë¾ÈÀ¸·Î, ÀÌ½Ä È帰¡ ¾Æ´Ñ ȯÀÚ¿¡°Ô´Â LVAD¸¦ ¸ñÀû ¿ä¹ýÀ¸·Î »ç¿ëÇϰí Ç¥ÁØ Ä¡·á·Î¼­ Àå±âÀûÀÎ Áö¿øÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ÀåÄ¡´Â ¼ö¼úÀûÀ¸·Î À̽ĵǾî Á½ɽǿ¡¼­ Ç÷¾×À» ²¨³» ´ëµ¿¸ÆÀ¸·Î º¸³»°í ½ÉÀåÀÇ ÁÖ½ÇÀÇ ÆßÇÁ ±â´ÉÀ» È¿°úÀûÀ¸·Î º¸Á¶Çϰųª ´ëÀÔÇÏ¿© ÀÛµ¿ÇÕ´Ï´Ù. LVAD ±â¼úÀÇ Áøº¸·Î ȯÀÚÀÇ QOL°ú »ýÁ¸À²ÀÌ Å©°Ô Çâ»óµÇ¾úÀ¸¸ç, ÀÌ ÀåÄ¡´Â ÁøÇàµÈ ½ÉºÎÀüÀ» °ü¸®ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿É¼ÇÀÌ µÇ¾ú½À´Ï´Ù.

±â¼ú Çõ½ÅÀº LVAD ½ÃÀåÀ» ¾î¶»°Ô Çü¼ºÇϴ°¡?

LVADÀÇ ¼³°è¿Í ±â´É¼º¿¡ ´ëÇÑ ±â¼úÀû Áøº¸´Â È¿´É°ú ȯÀÚ ÀûÇÕ¼ºÀ» ±ØÀûÀ¸·Î Çâ»ó½ÃÄ×½À´Ï´Ù. ÃֽŠLVAD´Â ÄÄÆÑÆ®Çϰí ħ½À¼ºÀÌ ³·°í Ç÷Àü ¹× °¨¿°°ú °°Àº ÀåÄ¡ °ü·Ã ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀÌ´Â ¿¬¼Ó È帧 ±â¼úÀ» °®Ãß°í ÀÖ½À´Ï´Ù. Àڱ⠺£¾î¸µ°ú À¯Ã¼ ¿ªÇÐ º£¾î¸µ°ú °°Àº ±â¼ú Çõ½ÅÀº ÀåºñÀÇ ¹°¸®Àû ¸¶¸ð¸¦ ÃÖ¼ÒÈ­ÇÏ°í »ç¿ë °¡´ÉÇÑ ¼ö¸í°ú ½Å·Ú¼ºÀ» ¿¬ÀåÇÕ´Ï´Ù. ¶ÇÇÑ ¹èÅ͸® ¼ö¸í°ú È޴뼺 Çâ»óÀ¸·Î ÀÎÇØ Á¦ÇÑÀÌ ¸¹¾Ò´ø ÀÌÀü ¸ðµ¨º¸´Ù ȯÀÚÀÇ ÀÚÀ¯µµ¿Í À̵¿¼ºÀÌ ³ô¾ÆÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû °³¼±À¸·Î LVADÀÇ º¸±Þ·üÀÌ ³ô¾ÆÁ³À» »Ó¸¸ ¾Æ´Ï¶ó ³ëÀΠȯÀÚ³ª º¹ÀâÇÑ °Ç°­ ÇÁ·ÎÆÄÀÏÀ» °¡Áø ȯÀÚ µî LVAD À̽ÄÀÇ ÀáÀçÀûÀÎ Èĺ¸ÀÚÃþµµ È®»êµÇ°í ÀÖ½À´Ï´Ù.

LVAD ½ÃÀå¿¡´Â ¾î¶² °úÁ¦¿Í ±âȸ°¡ Àִ°¡?

Å« Áøº¸¿¡µµ ºÒ±¸Çϰí, LVAD ½ÃÀåÀº ȯÀÚÀÇ °á°ú¿Í ±¤¹üÀ§ÇÑ º¸±Þ ¸ðµÎ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¹®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ÀÌ½Ä ÀýÂ÷ÀÇ Ä§½ÀÀû ¼ºÁú°ú ÃâÇ÷, ³úÁ¹Áß, °¨¿°°ú °°Àº ½É°¢ÇÑ ÇÕº´ÁõÀÇ À§ÇèÀº ÀáÀçÀûÀÎ Èĺ¸ÀÚ¸¦ ¸Á¼³ÀÌ´Â »ó´çÇÑ ¿ì·Á »çÇ×ÀÔ´Ï´Ù. ¶ÇÇÑ, Àåºñ º»Ã¼, ¼ö¼ú ¹× ¼ö¼ú ÈÄ °ü¸®¸¦ Æ÷ÇÔÇÑ ½ÅÈï ±¹°¡ÀÇ LVAD ºñ¿ëÀº ƯÈ÷ ÈÄÁø±¹¿¡¼­ ¸¹Àº ȯÀÚ¿Í °Ç°­ °ü¸® ½Ã½ºÅÛ¿¡¼­ ¾öû³ª°Ô ³ô½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ °úÁ¦´Â ½ÃÀå¿¡¼­ Çõ½Å°ú ¼ºÀåÀÇ ±âȸ°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö Àִ ħ½À¼ºÀÌ ³·°í ½Å·Ú¼ºÀÌ ³ô°í ºñ¿ë È¿À²ÀûÀÎ Àåºñ¸¦ »ý»êÇϱâ À§ÇÑ ¿¬±¸ °³¹ßÀÌ Ç×»ó ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ȯÀÚÀÇ °á°ú¸¦ Å©°Ô °³¼±ÇÒ ¼ö Àֱ⠶§¹®¿¡ ÇöÀçÀÇ ÇѰ踦 ±Øº¹ÇÒ ¼ö ÀÖ´Â Â÷¼¼´ë LVAD °³¹ß¿¡ ´ëÇÑ ÅõÀÚ¿Í °ü½ÉÀÌ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

LVAD ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ ÃËÁø

LVAD ½ÃÀåÀÇ ¼ºÀåÀº Àα¸µ¿ÅÂÀÇ µ¿Çâ, ±â¼úÀÇ Áøº¸, ÇコÄɾîÀÇ ÁøÈ­¸¦ ¹Ý¿µÇÑ ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ¼¼°è ½ÉºÎÀüÀÇ À¯º´·ü Áõ°¡´Â ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿Í ÇÔ²² LVAD¿Í °°Àº °í±Þ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ÃÊ·¡ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡¸¦ »ç¿ëÇϴ ȯÀÚÀÇ ¾ÈÀü¼º°ú QOLÀ» Çâ»ó½ÃŰ´Â ±â¼ú Çõ½ÅÀº ÀåÄ¡¸¦ ȯÀÚ¿Í ÀÓ»óÀÇÀÇ ¸ðµÎ¿¡°Ô ´õ¿í ¸Å·ÂÀûÀ¸·Î ¸¸µå´Â ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ȯÀÚ ¼±Åðú ¼ö¼ú Àü Ä¡·á °³¼±À¸·Î LVAD ȯÀÚÀÇ °á°ú°¡ ÃÖÀûÈ­µÇ¾î ÀÌ Ä¡·á¹ýÀÇ ¼º°ø·ü°ú ½Å·Ú¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ÀϺΠ±¹°¡¿¡¼­´Â °Ç°­ °ü¸® ÁöÃâ Áõ°¡¿Í °í±Þ ÀÇ·á º¸Çè Àû¿ë ¹üÀ§ È®´ë·Î LVAD°¡ º¸´Ù ±¤¹üÀ§ÇÑ È¯ÀÚ¿¡°Ô Ȱ¿ëµÇ°í ½ÃÀå ¼ºÀåÀ» ´õ¿í ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº Á¾ÇÕÀûÀ¸·Î LVAD ½ÃÀåÀÇ ¿ªµ¿ÀûÀÎ È®´ë¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, LVAD´Â Çö´ë ½ÉÀå Ä¡·á¿¡ ÇʼöÀûÀÎ ¿ä¼Ò°¡µÇ°í ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 13»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Left Ventricular Assist Device (LVAD) Market to Reach US$2.6 Billion by 2030

The global market for Left Ventricular Assist Device (LVAD) estimated at US$1.5 Billion in the year 2023, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2023-2030. Hospitals End-Use, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Clinics End-Use segment is estimated at 9.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$423.4 Million While China is Forecast to Grow at 7.2% CAGR

The Left Ventricular Assist Device (LVAD) market in the U.S. is estimated at US$423.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$402.7 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.8% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global Left Ventricular Assist Device (LVAD) Market - Key Trends & Drivers Summarized

What Are Left Ventricular Assist Devices (LVADs) and How Do They Support Heart Health?

Left Ventricular Assist Devices (LVADs) are mechanical pumps used to support heart function and blood flow in individuals with weakened hearts or severe heart failure. Typically employed when medical treatments are no longer effective, LVADs can be used as a bridge to heart transplantation, providing vital support while a patient awaits a donor heart. Alternatively, for patients who are not candidates for transplantation, LVADs can be used as a destination therapy, offering long-term support as a standard of care. These devices are surgically implanted and work by taking blood from the left ventricle and pumping it to the aorta, effectively aiding or taking over the pumping function of the heart's main chamber. Advances in LVAD technology have significantly improved the quality of life and survival rates for patients, making these devices a crucial option in managing advanced heart failure.

How Is Technological Innovation Shaping the LVAD Market?

Technological advancements in the design and functionality of LVADs have dramatically enhanced their effectiveness and patient compatibility. Modern LVADs are more compact, less invasive, and equipped with continuous flow technology that reduces the risk of device-related complications, such as blood clots and infections. Innovations such as magnetic and hydrodynamic bearings have minimized the physical wear on the device, extending their usable life and reliability. Additionally, improvements in battery life and portability allow patients more freedom and mobility than earlier models, which were more restrictive. These technological improvements have not only increased the adoption rates of LVADs but have also broadened the potential candidate pool for LVAD implantation, including older patients and those with complex health profiles.

What Challenges and Opportunities Exist Within the LVAD Market?

Despite significant advancements, the LVAD market faces challenges that affect both patient outcomes and broader adoption. The invasive nature of the implantation procedure and the risk of serious complications such as bleeding, stroke, and infection are considerable concerns that can deter potential candidates. Moreover, the cost of LVADs, including the device itself, surgery, and post-operative care, remains prohibitively high for many patients and healthcare systems, particularly in less developed countries. However, these challenges also present opportunities for innovation and growth within the market. There is a constant demand for research and development to produce less invasive, more reliable, and cost-effective devices that could address these issues. The potential for significant improvements in patient outcomes continues to drive investment and interest in developing next-generation LVADs that could overcome current limitations.

Growth in the LVAD Market Is Driven by Several Factors

The growth in the LVAD market is driven by several factors, reflecting a combination of demographic trends, technological advancements, and evolving healthcare practices. Increasing prevalence of heart failure worldwide, coupled with an aging global population, has resulted in a higher demand for advanced treatment options like LVADs. Technological innovations that enhance the safety and quality of life for patients using these devices are key growth drivers, making the devices more appealing to both patients and clinicians. Additionally, improvements in patient selection and pre-operative care have optimized outcomes for LVAD recipients, increasing the success rates and confidence in this treatment approach. Finally, growing healthcare expenditures and expanding insurance coverage for advanced medical treatments in several countries are making LVADs accessible to a broader range of patients, further stimulating market growth. These factors collectively contribute to the dynamic expansion of the LVAD market, making it a vital component of modern cardiac care.

Select Competitors (Total 13 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â